{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:14:58Z","timestamp":1790252098491,"version":"4.1.0"},"reference-count":419,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Antibacterial fluoroquinolones (FQs) are frequently used in treating infections. However, the value of FQs is debatable due to their association with severe adverse effects (AEs). The Food and Drug Administration (FDA) issued safety warnings concerning their side-effects in 2008, followed by the European Medicine Agency (EMA) and regulatory authorities from other countries. Severe AEs associated with some FQs have been reported, leading to their withdrawal from the market. New systemic FQs have been recently approved. The FDA and EMA approved delafloxacin. Additionally, lascufloxacin, levonadifloxacin, nemonoxacin, sitafloxacin, and zabofloxacin were approved in their origin countries. The relevant AEs of FQs and their mechanisms of occurrence have been approached. New systemic FQs present potent antibacterial activity against many resistant bacteria (including resistance to FQs). Generally, in clinical studies, the new FQs were well-tolerated with mild or moderate AEs. All the new FQs approved in the origin countries require more clinical studies to meet FDA or EMA requirements. Post-marketing surveillance will confirm or infirm the known safety profile of these new antibacterial drugs. The main AEs of the FQs class were addressed, highlighting the existing data for the recently approved ones. In addition, the general management of AEs when they occur and the rational use and caution of modern FQs were outlined.<\/jats:p>","DOI":"10.3390\/pharmaceutics15030804","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T03:28:06Z","timestamp":1677641286000},"page":"804","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4979-6903","authenticated-orcid":false,"given":"Aura","family":"Rusu","sequence":"first","affiliation":[{"name":"Pharmaceutical and Therapeutical Chemistry Department, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1281-3749","authenticated-orcid":false,"given":"Alexandra-Cristina","family":"Munteanu","sequence":"additional","affiliation":[{"name":"Department of General and Inorganic Chemistry, Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 6 Traian Vuia Str., 020956 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza-Mihaela","family":"Arb\u0103na\u0219i","sequence":"additional","affiliation":[{"name":"Pharmaceutical and Therapeutical Chemistry Department, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7165-5069","authenticated-orcid":false,"given":"Valentina","family":"Uivarosi","sequence":"additional","affiliation":[{"name":"Department of General and Inorganic Chemistry, Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 6 Traian Vuia Str., 020956 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"ref_1","unstructured":"Beale, J.M., and Block, J.H. (2010). Wilson and Gisvold\u2019s Textbook of Organic Medicinal and Pharmaceutical Chemistry, Wolters Kluwer Health. [12th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/oxfordjournals.jac.a020889","article-title":"Quinolone Generations: Natural History or Natural Selection?","volume":"46","author":"Ball","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bush, N.G., Diez-Santos, I., Abbott, L.R., and Maxwell, A. (2020). Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance. Molecules, 25.","DOI":"10.3390\/molecules25235662"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rusu, A., Lungu, I.-A., Moldovan, O.-L., Tanase, C., and Hancu, G. (2021). Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones\u2014Shaping the Fifth Generation. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081289"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ronald, A.R., and Low, D.E. (2003). Fluoroquinolone Antibiotics, Milestones in Drug Therapy; Birkh\u00e4user.","DOI":"10.1007\/978-3-0348-8103-6"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1021\/jm01240a021","article-title":"1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents","volume":"91","author":"Lesher","year":"1962","journal-title":"J. Med. Pharm. Chem."},{"key":"ref_7","unstructured":"Brunton, L.L., Hilal-Dandan, R., and Knollmann, B.C. (2017). Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics, McGraw-Hill Education. [13th ed.]."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1039\/C9MD00120D","article-title":"Quinolone Antibiotics","volume":"10","author":"Pham","year":"2019","journal-title":"Medchemcomm"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1099\/00222615-44-5-320","article-title":"Quinolones: Structure-Activity Relationships and Future Predictions","volume":"44","author":"Tillotson","year":"1996","journal-title":"J. Med. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1086\/321846","article-title":"Quinolone Molecular Structure-Activity Relationships: What We Have Learned about Improving Antimicrobial Activity","volume":"33","author":"Peterson","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","unstructured":"Domagala, J.M., and Hagen, S.E. (2003). Quinolone Antimicrobial Agents, American Society of Microbiology Press. [3rd ed.]."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1016\/j.ejmech.2010.09.036","article-title":"Synthesis and in Vitro Antimicrobial Evaluation of Novel Fluoroquinolone Derivatives","volume":"45","author":"Srinivasan","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_13","first-page":"28","article-title":"Study of Antimicrobial Quinolones and Structure Activity Relationship of Anti-Tubercular Compounds","volume":"4","author":"Asif","year":"2015","journal-title":"Res. Rev. J. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Andriole, V.T. (2000). The Quinolones, Academic Press. [3rd ed.].","DOI":"10.1016\/B978-012059517-4\/50017-9"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of Quinolone Action and Resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1086\/314056","article-title":"Mechanisms of Action and Resistance of Older and Newer Fluoroquinolones","volume":"31","author":"Hooper","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"a025320","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1099\/jmm.0.000475","article-title":"Mechanisms of Quinolone Action and Resistance: Where Do We Stand?","volume":"66","author":"Correia","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.survophthal.2004.01.005","article-title":"Fluoroquinolones: Mechanism of Action, Classification, and Development of Resistance","volume":"49","author":"Blondeau","year":"2004","journal-title":"Surv. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1751-7915.2008.00063.x","article-title":"Mechanism of Action of and Resistance to Quinolones","volume":"2","author":"Madurga","year":"2009","journal-title":"Microb. Biotechnol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kocsis, B., Guly\u00e1s, D., and Szab\u00f3, D. (2021). Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline. Antibiotics, 10.","DOI":"10.3390\/antibiotics10121506"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"119552","DOI":"10.1016\/j.ijpharm.2020.119552","article-title":"Development of Besifloxacin HCl Loaded Nanofibrous Ocular Inserts for the Treatment of Bacterial Keratitis: In Vitro, Ex Vivo and in Vivo Evaluation","volume":"585","author":"Polat","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1358\/dot.2020.56.6.3137167","article-title":"Lascufloxacin Hydrochloride to Treat Bacterial Infection","volume":"56","author":"Thakare","year":"2020","journal-title":"Drugs Today"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102346","DOI":"10.1016\/j.anaerobe.2021.102346","article-title":"In Vivo Pharmacodynamics of Lascufloxacin and Levofloxacin against Streptococcus Pneumoniae and Prevotella Intermedia in a Pneumonia Mixed-Infection Mouse Model","volume":"69","author":"Hagihara","year":"2021","journal-title":"Anaerobe"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/10408347.2018.1429885","article-title":"Besifloxacin: A Critical Review of Its Characteristics, Properties, and Analytical Methods","volume":"48","author":"Totoli","year":"2018","journal-title":"Crit. Rev. Anal. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"DeCory, H.H., Sanfilippo, C.M., Proskin, H.M., and Blondeau, J.M. (2020). Characterization of Baseline Polybacterial versus Monobacterial Infections in Three Randomized Controlled Bacterial Conjunctivitis Trials and Microbial Outcomes with Besifloxacin Ophthalmic Suspension 0.6%. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237603"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40265-015-0384-z","article-title":"Finafloxacin: First Global Approval","volume":"75","author":"McKeage","year":"2015","journal-title":"Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40265-014-0270-0","article-title":"Nemonoxacin: First Global Approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Chang, L.-W., Hsu, M.-C., and Zhang, Y.-Y. (2019). Nemonoxacin (Taigexyn\u00ae): A New Non-Fluorinated Quinolone, IntechOpen.","DOI":"10.5772\/intechopen.88455"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jmii.2018.11.006","article-title":"Integrated Safety Summary of Phase II and III Studies Comparing Oral Nemonoxacin and Levofloxacin in Community-Acquired Pneumonia","volume":"52","author":"Cheng","year":"2019","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_31","unstructured":"Yan, A., and Bryant, E.E. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_32","unstructured":"(2021, August 12). Office of the Commissioner FDA Updates Warnings for Fluoroquinolone Antibiotics, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-updates-warnings-fluoroquinolone-antibiotics."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejim.2020.01.009","article-title":"Assessing the Association between Fluoroquinolones and Emerging Adverse Drug Reactions Raised by Regulatory Agencies: An Umbrella Review","volume":"75","author":"Gatti","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_34","unstructured":"Francisco, E.M. (2021, August 12). Fluoroquinolone and Quinolone Antibiotics: PRAC Recommends New Restrictions on Use Following Review of Disabling Potentially Long-Lasting Side Effects. Available online: https:\/\/www.ema.europa.eu\/en\/news\/fluoroquinolone-quinolone-antibiotics-prac-recommends-new-restrictions-use-following-review."},{"key":"ref_35","unstructured":"Francisco, E.M. (2021, August 12). Disabling and Potentially Permanent Side Effects Lead to Suspension or Restrictions of Quinolone Fluoroquinolone Antibiotics. Available online: https:\/\/www.ema.europa.eu\/en\/news\/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone."},{"key":"ref_36","unstructured":"(2022, November 01). Dassault Syst\u00e8mes BIOVIA Draw for Academics. Available online: https:\/\/discover.3ds.com\/biovia-draw-academic."},{"key":"ref_37","first-page":"3","article-title":"History of Quinolones and Their Side Effects","volume":"47","author":"Rubinstein","year":"2001","journal-title":"CHE"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lungu, I.-A., Moldovan, O.-L., Biri\u0219, V., and Rusu, A. (2022). Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081749"},{"key":"ref_39","first-page":"39","article-title":"Besifloxacin the fourth generation fluoroquinolone: A review","volume":"4","author":"Singh","year":"2014","journal-title":"J. Drug Deliv. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jiac.2021.03.026","article-title":"In Vitro Activities and Spectrum of Lascufloxacin (KRP-AM1977) against Anaerobes","volume":"27","author":"Tanaka","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_41","first-page":"30","article-title":"Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study","volume":"68","author":"Bhatia","year":"2020","journal-title":"J. Assoc. Physicians India"},{"key":"ref_42","unstructured":"Sweetman, S.C. (2009). Martindale: The Complete Drug Reference, Pharmaceutical Press. [36th ed.]."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s13555-014-0062-1","article-title":"Efficacy and Safety of Nadifloxacin for Bacterial Skin Infections: Results from Clinical and Post-Marketing Studies","volume":"4","author":"Narayanan","year":"2014","journal-title":"Dermatol. Ther."},{"key":"ref_44","unstructured":"Limberakis, C. (2007). The Art of Drug Synthesis, John Wiley & Sons, Ltd."},{"key":"ref_45","first-page":"495","article-title":"Clinical Use of Gatifloxacin Ophthalmic Solution for Treatment of Bacterial Conjunctivitis","volume":"5","author":"Cervantes","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"ref_46","unstructured":"(2022, August 05). Drug Approval Package: Zymar (Gatifloxacin) NDA #021493, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/021493_Zymar.cfm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40123-016-0046-6","article-title":"Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections","volume":"5","author":"Mah","year":"2016","journal-title":"Ophthalmol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/jac\/33.4.685","article-title":"Structure-Activity and Structure-Side-Effect Relationships for the Quinolone Antibacterials","volume":"33","author":"Domagala","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/clinids\/18.6.946","article-title":"Temafloxacin Syndrome: Review of 95 Cases","volume":"18","author":"Blum","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical Review of Delafloxacin: A Novel Anionic Fluoroquinolone","volume":"73","author":"Mogle","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1093\/cid\/ciy1080","article-title":"Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections","volume":"68","author":"Bassetti","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1016\/j.bmc.2019.05.038","article-title":"Fluoroquinolones Structural and Medicinal Developments (2013\u20132018): Where Are We Now?","volume":"27","author":"Suaifan","year":"2019","journal-title":"Bioorganic Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1128\/AAC.45.10.2703-2709.2001","article-title":"Enhancement of Fluoroquinolone Activity by C-8 Halogen and Methoxy Moieties: Action against a Gyrase Resistance Mutant of Mycobacterium Smegmatis and a Gyrase-Topoisomerase IV Double Mutant of Staphylococcus Aureus","volume":"45","author":"Lu","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","unstructured":"Thomas, G. (2008). Medicinal Chemistry: An Introduction, Wiley. [2nd ed.]."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2147\/OPTH.S44085","article-title":"Contribution of the R8 Substituent to the in Vitro Antibacterial Potency of Besifloxacin and Comparator Ophthalmic Fluoroquinolones","volume":"7","author":"Haas","year":"2013","journal-title":"Clin. Ophthalmol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2174\/156802609789630947","article-title":"Quinolones: Action and Resistance Updated","volume":"9","author":"Drlica","year":"2009","journal-title":"Curr. Top Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ejmech.2013.01.057","article-title":"Antibacterial Action of Quinolones: From Target to Network","volume":"66","author":"Cheng","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone Resistance: Mechanisms, Impact on Bacteria, and Role in Evolutionary Success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1365-2958.2006.05275.x","article-title":"Lethal Fragmentation of Bacterial Chromosomes Mediated by DNA Gyrase and Quinolones","volume":"61","author":"Malik","year":"2006","journal-title":"Mol. Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"10064","DOI":"10.1073\/pnas.1901730116","article-title":"Post-Stress Bacterial Cell Death Mediated by Reactive Oxygen Species","volume":"116","author":"Hong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jac\/dkz485","article-title":"Reactive Oxygen Species Play a Dominant Role in All Pathways of Rapid Quinolone-Mediated Killing","volume":"75","author":"Hong","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_62","unstructured":"Rodr\u00edguez-Rosado, A.I., Valencia, E.Y., Rodr\u00edguez-Rojas, A., Costas, C., Galhardo, R.S., Bl\u00e1zquez, J., and Rodr\u00edguez-Beltr\u00e1n, J. (2018). Reactive Oxygen Species Are Major Contributors to SOS-Mediated Mutagenesis Induced by Fluoroquinolones. bioRxiv, 428961."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e8023935","DOI":"10.1155\/2017\/8023935","article-title":"Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications","volume":"2017","author":"Michalak","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.EEM.0000547204.98717.6a","article-title":"InFocus: Fluoroquinolone Side Effects Just Got Scarier","volume":"40","author":"Roberts","year":"2018","journal-title":"Emerg. Med. News"},{"key":"ref_65","unstructured":"EMA (2021, August 12). Quinolone- and Fluoroquinolone-Containing Medicinal Products. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/quinolone-fluoroquinolone-containing-medicinal-products."},{"key":"ref_66","unstructured":"(2022, September 16). Center for Drug Evaluation and Research FDA Drug Safety Communication: FDA Updates Warnings for Oral and Injectable Fluoroquinolone Antibiotics Due to Disabling Side Effects. FDA 2019, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics."},{"key":"ref_67","first-page":"22","article-title":"The FDA Revises Boxed Warning For Fluoroquinolones-Again","volume":"116","author":"Aschenbrenner","year":"2016","journal-title":"Am. J. Nurs."},{"key":"ref_68","unstructured":"Center for Drug Evaluation and Research (2022, September 20). FDA Reinforces Safety Information about Serious Low Blood Sugar Levels and Mental Health Side Effects with Fluoroquinolone Antibiotics; Requires Label Changes. FDA 2018, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side."},{"key":"ref_69","unstructured":"Office of the Commissioner FDA (2022, September 19). In Brief: FDA Warns That Fluoroquinolone Antibiotics Can Cause Aortic Aneurysm in Certain Patients. FDA 2019, Available online: https:\/\/www.fda.gov\/news-events\/fda-brief\/fda-brief-fda-warns-fluoroquinolone-antibiotics-can-cause-aortic-aneurysm-certain-patients."},{"key":"ref_70","unstructured":"EMA (2022, September 20). Meeting Highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 1\u20134 October 2018. Available online: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-1-4-october-2018."},{"key":"ref_71","first-page":"135","article-title":"FDA Adds \u201cBlack Box\u201d Warning Label to Fluoroquinolone Antibiotics","volume":"337","author":"Tanne","year":"2008","journal-title":"BMJ"},{"key":"ref_72","unstructured":"Waknine, Y. (2022, September 21). Fluoroquinolones Earn Black Box Warning for Tendon-Related Adverse Effects. Available online: https:\/\/www.medscape.com\/viewarticle\/577302."},{"key":"ref_73","unstructured":"(2022, September 21). Center for Drug Evaluation and Research Postmarket Drug Safety Information for Patients and Providers\u2014Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs [Ciprofloxacin (Marketed as Cipro and Generic Ciprofloxacin), Ciprofloxacin Extended-Release (Marketed as Cipro XR and Proquin XR), Gemifloxacin (Marketed as Factive), Levofloxacin (Marketed as Levaquin), Moxifloxacin (Marketed as Avelox), Norfloxacin (Marketed as Noroxin), and Ofloxacin (Marketed as Floxin)], Available online: http:\/\/wayback.archive-it.org\/7993\/20161022101528\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm126085.htm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/11593110-000000000-00000","article-title":"Fluoroquinolone-Associated Myasthenia Gravis Exacerbation","volume":"34","author":"Jones","year":"2011","journal-title":"Drug Saf."},{"key":"ref_75","unstructured":"(2022, September 21). Center for Drug Evaluation and Research Drug Safety and Availability\u2014FDA Drug Safety Communication: FDA Requires Label Changes to Warn of Risk for Possibly Permanent Nerve Damage from Antibacterial Fluoroquinolone Drugs Taken by Mouth or by Injection, Available online: http:\/\/wayback.archive-it.org\/7993\/20161022101530\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm365050.htm."},{"key":"ref_76","unstructured":"Center for Drug Evaluation and Research (2022, September 21). FDA Drug Safety Communication: FDA Advises Restricting Fluoroquinolone Antibiotic Use for Certain Uncomplicated Infections; Warns about Disabling Side Effects That Can Occur Together. FDA 2016, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain."},{"key":"ref_77","unstructured":"FDA (2022, October 10). Drug Safety Communication FDA Warns about Increased Risk of Ruptures or Tears in the Aorta Blood Vessel with Fluoroquinolone Antibiotics in Certain Patients, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics."},{"key":"ref_78","unstructured":"EMA (2022, September 20). Systemic and Inhaled Fluoroquinolones: Risk of Heart Valve Regurgitation\/Incompetence. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/systemic-inhaled-fluoroquinolones-risk-heart-valve-regurgitationincompetence."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2019.07.035","article-title":"Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation","volume":"74","author":"Etminan","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jtcvs.2018.08.079","article-title":"Induction of Human Aortic Myofibroblast-Mediated Extracellular Matrix Dysregulation: A Potential Mechanism of Fluoroquinolone-Associated Aortopathy","volume":"157","author":"Guzzardi","year":"2019","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_81","unstructured":"(2022, July 19). Systemic and Inhaled Fluoroquinolones: Small Risk of Heart Valve Regurgitation; Consider Other Therapeutic Options First in Patients at Risk, Available online: https:\/\/www.gov.uk\/drug-safety-update\/systemic-and-inhaled-fluoroquinolones-small-risk-of-heart-valve-regurgitation-consider-other-therapeutic-options-first-in-patients-at-risk."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/eurheartj\/ehab374","article-title":"Oral Fluoroquinolones and Risk of Aortic or Mitral Regurgitation: A Nationwide Nested Case-Control Study","volume":"42","author":"Strange","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ijantimicag.2018.04.014","article-title":"Adverse Events of Fluoroquinolones vs. Other Antimicrobials Prescribed in Primary Care: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"52","author":"Tandan","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/OLQ.0000000000000971","article-title":"Efficacy and Safety of Single-Dose Oral Delafloxacin Compared With Intramuscular Ceftriaxone for Uncomplicated Gonorrhea Treatment: An Open-Label, Noninferiority, Phase 3, Multicenter, Randomized Study","volume":"46","author":"Hook","year":"2019","journal-title":"Sex Transm Dis"},{"key":"ref_85","first-page":"68","article-title":"Phase III Double-Blind Comparative Study of Lascufloxacin versus Levofloxacin in Patients with Sinusitis","volume":"68","author":"Kurono","year":"2020","journal-title":"Jpn. J. Chemother."},{"key":"ref_86","unstructured":"(2022, October 05). Health Canada Summary Safety Review\u2014Oral Fluoroquinolones\u2014Assessing the Potential Risk of Retinal Detachment. Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/safety-reviews\/summary-safety-review-oral-fluoroquinolones-assessing-potential-risk-retinal.html."},{"key":"ref_87","unstructured":"(2022, October 05). Health Canada Summary Safety Review\u2014Fluoroquinolones\u2014Assessing the Potential Risk of Persistent and Disabling Side Effects. Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/safety-reviews\/summary-safety-review-fluoroquinolones-assessing-potential-risk-persistent-disabling-effects.html."},{"key":"ref_88","unstructured":"(2022, October 05). Medicines and Healthcare products Regulatory Agency Fluoroquinolone Antibiotics: New Restrictions and Precautions for Use Due to Very Rare Reports of Disabling and Potentially Long-Lasting or Irreversible Side Effects, Available online: https:\/\/www.gov.uk\/drug-safety-update\/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3201\/eid1809.111515","article-title":"Control of Fluoroquinolone Resistance through Successful Regulation, Australia","volume":"18","author":"Cheng","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"ref_90","unstructured":"(2022, October 05). Therapeutic Goods Administration (TGA) Fluoroquinolone Antibiotics and Risk of Aortic Aneurysm\/Dissection, Available online: https:\/\/www.tga.gov.au\/news\/safety-updates\/fluoroquinolone-antibiotics-and-risk-aortic-aneurysmdissection."},{"key":"ref_91","unstructured":"(2022, October 05). Therapeutic Goods Administration (TGA) Update\u2014Fluoroquinolone Antibiotics and Adverse Events, Available online: https:\/\/www.tga.gov.au\/news\/safety-updates\/update-fluoroquinolone-antibiotics-and-adverse-events."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/jlme.12079","article-title":"Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the U.S., 1980\u20132009","volume":"41","author":"Outterson","year":"2013","journal-title":"J. Law. Med. Ethics"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1128\/AAC.33.10.1778","article-title":"Adverse Reactions in a Dose-Ranging Study with a New Long-Acting Fluoroquinolone, Fleroxacin","volume":"33","author":"Bowie","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"201S","DOI":"10.1016\/S0002-9343(20)31165-7","article-title":"Safety of Fleroxacin in Clinical Trials","volume":"94","author":"Geddes","year":"1993","journal-title":"Am. J. Med."},{"key":"ref_95","first-page":"618","article-title":"Drug-induced pneumonitis with eosinophilic infiltration due to tosufloxacin tosilate","volume":"36","author":"Kimura","year":"1998","journal-title":"J. Jpn. Respir. Soc."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.5021\/ad.2011.23.S3.S404","article-title":"Toxic Epidermal Necrolysis Associated with Sorafenib and Tosufloxacin in a Patient with Hepatocellular Carcinoma","volume":"23","author":"Choi","year":"2011","journal-title":"Ann. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1086\/428055","article-title":"Antimicrobial Safety: Focus on Fluoroquinolones","volume":"41","author":"Owens","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_98","unstructured":"Aronson, J.K. (2015). Meyler\u2019s Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, Elsevier."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1086\/319379","article-title":"Antimicrobial Safety and Tolerability: Differences and Dilemmas","volume":"32","author":"Mandell","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00002018-199308010-00002","article-title":"The Withdrawal of Temafloxacin","volume":"8","author":"Finch","year":"1993","journal-title":"Drug Saf."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/1011-1344(95)07246-2","article-title":"The UVR Wavelength Dependence for Lomefloxacin Photosensitization of Human Skin","volume":"32","author":"Young","year":"1996","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/clpt.1994.180","article-title":"Photoreactions with a Fluoroquinolone Antimicrobial: Evening versus Morning Dosing","volume":"56","author":"Lowe","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_103","unstructured":"Petersen, U. (2006). Analogue-Based Drug Discovery, John Wiley & Sons, Ltd."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jac\/37.suppl_A.161","article-title":"Overview of Electrocardiographic and Cardiovascular Safety Data for Sparfloxacin. Sparfloxacin Safety Group","volume":"37","author":"Jaillon","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/37.suppl_A.145","article-title":"Safety Profile of Sparfloxacin in the Treatment of Respiratory Tract Infections","volume":"37","author":"Rubinstein","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0149-2918(00)88275-2","article-title":"Safety Profile of Sparfloxacin, a New Fluoroquinolone Antibiotic","volume":"21","author":"Lipsky","year":"1999","journal-title":"Clin. Ther."},{"key":"ref_107","first-page":"2741","article-title":"New Classification and Update on the Quinolone Antibiotics","volume":"61","author":"King","year":"2000","journal-title":"Am. Fam. Physician"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/pds.2155","article-title":"Market Withdrawal of New Molecular Entities Approved in the United States from 1980 to 2009","volume":"20","author":"Qureshi","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1345\/aph.19305","article-title":"Alatrofloxacin-Induced Seizures during Slow Intravenous Infusion","volume":"34","author":"Melvani","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1345\/aph.19224","article-title":"Severe Thrombocytopenia Associated with Alatrofloxacin","volume":"34","author":"Gales","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jac\/48.1.67","article-title":"Efficacy and Safety of Gemifloxacin in the Treatment of Community-Acquired Pneumonia: A Randomized, Double-Blind Comparison with Trovafloxacin","volume":"48","author":"File","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/PL00011876","article-title":"Acute Liver Failure Due to Trovafloxacin: CT Findings","volume":"8","author":"Pannu","year":"2001","journal-title":"Emerg. Radiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/40.suppl_1.83","article-title":"Safety Profile of Grepafloxacin Compared with Other Fluoroquinolones","volume":"40","author":"Stahlmann","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_114","first-page":"806","article-title":"Potassium Current Antagonist Properties and Proarrhythmic Consequences of Quinolone Antibiotics","volume":"296","author":"Anderson","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_115","first-page":"207","article-title":"The New Fluoroquinolones: A Critical Review","volume":"10","author":"Zhanel","year":"1999","journal-title":"Can. J. Infect. Dis."},{"key":"ref_116","unstructured":"FDA (2022, September 14). Determination That TEQUIN (Gatifloxacin) Was Withdrawn From Sale for Reasons of Safety or Effectiveness, Available online: https:\/\/www.federalregister.gov\/documents\/2008\/09\/09\/E8-20938\/determination-that-tequin-gatifloxacin-was-withdrawn-from-sale-for-reasons-of-safety-or."},{"key":"ref_117","first-page":"54","article-title":"Safety of Fluoroquinolones: An Update","volume":"13","author":"Mandell","year":"2002","journal-title":"Can. J. Infect. Dis."},{"key":"ref_118","unstructured":"EMA (2022, September 22). Questions and Answers on the Withdrawal of the Marketing Authorisation Application for Factive Gemifloxacin, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-withdrawal-marketing-authorisation-application-factive-gemifloxacin_en.pdf."},{"key":"ref_119","unstructured":"EMA (2022, September 22). Menarini International Operations Luxembourg Withdraws Its Marketing Authorisation Application for Factive (Gemifloxacin), Available online: https:\/\/www.ema.europa.eu\/en\/news\/menarini-international-operations-luxembourg-withdraws-its-marketing-authorisation-application."},{"key":"ref_120","unstructured":"Center for Drug Evaluation and Research (2022, September 22). CDER Division of Drug Information, Available online: https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/cder-division-drug-information."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.japh.2018.08.011","article-title":"Fluoroquinolones: A Hot Topic for Pharmacists and the Food and Drug Administration\u2019s Division of Drug Information","volume":"59","author":"Molnar","year":"2019","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/17469872.1.5.643","article-title":"Acne Vulgaris and Bacterial Skin Infections: Review of the Topical Quinolone Nadifloxacin","volume":"1","author":"Nenoff","year":"2006","journal-title":"Expert Rev. Dermatol."},{"key":"ref_123","unstructured":"EMA (2021, June 11). EMA\/150639\/2017 Nadifloxacin, List of Nationally Authorised Medicinal Products, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/nadifloxacin-list-nationally-authorised-medicinal-products-psusa\/00002102\/201605_en.pdf."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"112931","DOI":"10.1016\/j.ejmech.2020.112931","article-title":"Polypharmacological Drug Actions of Recently FDA Approved Antibiotics","volume":"209","author":"Wetzel","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_125","unstructured":"(2022, September 22). Center for Drug Evaluation and Research Drug Trial Snapshot: Xepi. FDA 2020, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trial-snapshot-xepi."},{"key":"ref_126","unstructured":"(2022, September 22). Troy Brown FDA Approves Ozenoxacin Cream for Impetigo. Available online: https:\/\/www.medscape.com\/viewarticle\/890180."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1517\/14656566.7.14.1957","article-title":"Nadifloxacin: A Quinolone for Topical Treatment of Skin Infections and Potential for Systemic Use of Its Active Isomer, WCK 771","volume":"7","author":"Jacobs","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1358\/dot.2008.44.7.1219561","article-title":"Sitafloxacin Hydrate for Bacterial Infections","volume":"44","author":"Anderson","year":"2008","journal-title":"Drugs Today"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Chen, C.-K., Cheng, I.-L., Chen, Y.-H., and Lai, C.-C. (2020). Efficacy and Safety of Sitafloxacin in the Treatment of Acute Bacterial Infection: A Meta-Analysis of Randomized Controlled Trials. Antibiotics, 9.","DOI":"10.3390\/antibiotics9030106"},{"key":"ref_130","unstructured":"(2022, September 26). NCATS Inxight Drugs\u2014SITAFLOXACIN. Available online: https:\/\/drugs.ncats.io\/drug\/9TD681796G."},{"key":"ref_131","first-page":"103","article-title":"Clinical Study of Sitafloxacin in Febrile Complicated Pyelonephritis","volume":"56","author":"Kawada","year":"2008","journal-title":"Jpn. J. Chemother."},{"key":"ref_132","first-page":"130","article-title":"Clinical Study of Sitafloxacin in Male Nongonococcal Urethritis","volume":"56","author":"Kawada","year":"2008","journal-title":"Jpn. J. Chemother."},{"key":"ref_133","first-page":"146","article-title":"Clinical Study of Sitafloxacin in the Treatment of Male Gonococcal Urethritis","volume":"56","author":"Onodera","year":"2008","journal-title":"Jpn. J. Chemother."},{"key":"ref_134","first-page":"139","article-title":"Clinical Study of Sitafloxacin in Treatment of Cervicitis with Chlamydia Trachomatis","volume":"56","author":"Matsuda","year":"2008","journal-title":"Jpn. J. Chemother."},{"key":"ref_135","first-page":"81","article-title":"Comparative Study on Sitafloxacin and Levofloxacin in Complicated Urinary Tract Infections","volume":"56","author":"Kawada","year":"2008","journal-title":"Jpn. J. Chemother."},{"key":"ref_136","first-page":"92","article-title":"Dose-Comparative Study of Sitafloxacin in Complicated Urinary Tract Infections","volume":"56","author":"Kawada","year":"2008","journal-title":"Jpn. J. Chemother."},{"key":"ref_137","first-page":"63","article-title":"Open Study of Sitafloxacin in Patients with Respiratory Tract Infections","volume":"56","author":"Saito","year":"2008","journal-title":"Jpn. J. Chemother."},{"key":"ref_138","first-page":"121","article-title":"Oral Tissue Distribution, Efficacy, and Safety of Sitafloxacin in Patients with Dentistry and Oral Surgery Infection","volume":"56","author":"Sasaki","year":"2008","journal-title":"Jpn. J. Chemother."},{"key":"ref_139","first-page":"49","article-title":"Phase III Double-Blind Comparative Study of Sitafloxacin versus Tosufloxacin in Patients with Community-Acquired Pneumonia","volume":"56","author":"Saito","year":"2008","journal-title":"Jpn. J. Chemother."},{"key":"ref_140","first-page":"36","article-title":"Double-Blind Comparative Study of Sitafloxacin versus Levofloxacin in Patients with Respiratory Tract Infection","volume":"56","author":"Kobayashi","year":"2008","journal-title":"Jpn. J. Chemother."},{"key":"ref_141","unstructured":"FDA, N. (2021, June 05). 22308\/S-013 Besifloxacin Label 2009, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022308s013lbl.pdf."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"OED.S4102","DOI":"10.4137\/OED.S4102","article-title":"Besifloxacin Ophthalmic Suspension: Emerging Evidence of Its Therapeutic Value in Bacterial Conjunctivitis","volume":"3","author":"Khimdas","year":"2011","journal-title":"Ophthalmol. Eye Dis."},{"key":"ref_143","unstructured":"Therapeutic Goods Administration (TGA) (2022, September 27). AusPAR: Besifloxacin Hydrochloride, Available online: https:\/\/www.tga.gov.au\/resources\/auspar\/auspar-besifloxacin-hydrochloride."},{"key":"ref_144","unstructured":"FDA (2021, June 07). Drug Approval Package Xtoro (Finafloxacin) Otic Suspension, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206307Orig1s000TOC.cfm."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e01470-19","DOI":"10.1128\/AAC.01470-19","article-title":"Demonstration of the Broad-Spectrum In Vitro Activity of Finafloxacin against Pathogens of Biodefense Interest","volume":"63","author":"Barnes","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e02294-20","DOI":"10.1128\/AAC.02294-20","article-title":"Finafloxacin Is an Effective Treatment for Inhalational Tularemia and Plague in Mouse Models of Infection","volume":"65","author":"Barnes","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_147","unstructured":"(2022, September 26). Product-Taigexyn\u00ae-TaiGen Biotechnology\u2014A Pharmaceutical Company Dedicating in Drug Discovery. Available online: https:\/\/www.taigenbiotech.com\/en\/product\/detail\/Taigexyn."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1128\/AAC.02972-14","article-title":"Safety, Tolerability, and Pharmacokinetics of Intravenous Nemonoxacin in Healthy Chinese Volunteers","volume":"58","author":"Cao","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1358\/dot.2016.52.9.2530595","article-title":"Zabofloxacin for Chronic Bronchitis","volume":"52","author":"Kocsis","year":"2016","journal-title":"Drugs Today"},{"key":"ref_150","unstructured":"(2022, September 27). Dongwha News Dong Wha Pharm\u2019s Quinolone Antibacterial Agent, \u201cZabolante,\u201d Wins at the 19th KNDA. Available online: https:\/\/www.dong-wha.co.kr\/english\/customer\/dnews\/content.asp?t_idx=1139."},{"key":"ref_151","unstructured":"(2022, September 27). Dong Wha Pharmaceutical CO., LTD Antibiotics. Available online: https:\/\/www.dong-wha.co.kr\/english\/product\/content.asp?t_idx=545&t_page=1&d=&b=10&s=11."},{"key":"ref_152","unstructured":"FDA (2021, June 05). Baxdela (Delafloxacin) Tablets and Injection, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208610Orig1s000,208611Orig1s000TOC.cfm."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-020-01358-0","article-title":"Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"ref_154","unstructured":"EMA (2022, September 27). Quofenix. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/quofenix."},{"key":"ref_155","first-page":"246","article-title":"Delafloxacin (Baxdela) for Skin Infections","volume":"98","author":"Eudaley","year":"2018","journal-title":"Am. Fam. Physician"},{"key":"ref_156","unstructured":"FDA (2022, September 27). XEPITM (Ozenoxacin) Cream, for Topical Use 2017, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208945lbl.pdf."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Garcia Ron, G., and Villa Arranz, M. (2022). New Therapeutic Applications of Ozenoxacin in Superficial Skin Infections. Dermatol. Rep., 14.","DOI":"10.4081\/dr.2021.9289"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000504536","article-title":"Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents","volume":"236","author":"Torrelo","year":"2020","journal-title":"Dermatology"},{"key":"ref_159","unstructured":"Ogihara, S. (2021, June 25). NHI Drug Price Listing and Release of Oral Quinolone Antibacterial Agent \u201cLasvic\u00aeTablets 75mg\u201d. Available online: https:\/\/www.kyorin-pharm.co.jp\/en\/news\/a329f0ae64024c1173f40660eede0efb37f1cbb0.pdf."},{"key":"ref_160","unstructured":"Ogihara, S., and Liang, X. (2022, September 28). KYORIN and Nanjing Neiwa Faith Signed License Agreement for Lascufloxacin in China. 2022, 1. Available online: https:\/\/www.kyorin-pharm.co.jp\/en\/news\/KYORIN%20and%20Nanjing%20Neiwa%20Faith%20Signed%20License%20Agreement%20for%20Lascufloxacin%20in%20China.pdf."},{"key":"ref_161","first-page":"1","article-title":"An Overview of Oral Lascufloxacin, a Novel Quinolone Antibiotic","volume":"68","author":"Tateda","year":"2020","journal-title":"Jpn. J. Chemother."},{"key":"ref_162","first-page":"2156","article-title":"Levonadifloxacin, a Recently Approved Benzoquinolizine Fluoroquinolone, Exhibits Potent in Vitro Activity against Contemporary Staphylococcus Aureus Isolates and Bengal Bay Clone Isolates Collected from a Large Indian Tertiary Care Hospital","volume":"75","author":"Bakthavatchalam","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1358\/dot.2020.56.9.3168445","article-title":"Levonadifloxacin Arginine Salt to Treat MRSA Infection and Acute Bacterial Skin and Skin Structure Infection","volume":"56","author":"Saxena","year":"2020","journal-title":"Drugs Today"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Koulenti, D., Xu, E., Song, A., Sum Mok, I.Y., Karageorgopoulos, D.E., Armaganidis, A., Tsiodras, S., and Lipman, J. (2020). Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 8.","DOI":"10.3390\/microorganisms8020191"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"378","DOI":"10.7196\/SAMJ.2019.v109i6.14002","article-title":"Rational Use of the Fluoroquinolones","volume":"109","author":"Richards","year":"2019","journal-title":"S. Afr. Med. J."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Kuula, L.S.M., Viljemaa, K.M., Backman, J.T., and Blom, M. (2019). Fluoroquinolone-Related Adverse Events Resulting in Health Service Use and Costs: A Systematic Review. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216029"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1469-0691.2005.01131.x","article-title":"Quinolones in 2005: An Update","volume":"11","author":"Michot","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1086\/515104","article-title":"Fluoroquinolone Toxicity Profiles: A Review Focusing on Newer Agents","volume":"28","author":"Lipsky","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/AAC.48.3.799-803.2004","article-title":"New Findings on the Structure-Phototoxicity Relationship and Photostability of Fluoroquinolones with Various Substituents at Position 1","volume":"48","author":"Hayashi","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_170","first-page":"123","article-title":"Quinolones: Recent Structural and Clinical Developments","volume":"4","author":"Emami","year":"2005","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/WNL.0000000000002023","article-title":"Seizures as Adverse Events of Antibiotic Drugs: A Systematic Review","volume":"85","author":"Sutter","year":"2015","journal-title":"Neurology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/14740338.2019.1665022","article-title":"An Evaluation of Reports of Ciprofloxacin, Levofloxacin, and Moxifloxacin-Association Neuropsychiatric Toxicities, Long-Term Disability, and Aortic Aneurysms\/Dissections Disseminated by the Food and Drug Administration and the European Medicines Agency","volume":"18","author":"Bennett","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jacc.2018.06.067","article-title":"Oral Fluoroquinolone and the Risk of Aortic Dissection","volume":"72","author":"Lee","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Londhe, A.A., Holy, C.E., Weaver, J., Fonseca, S., Villasis, A., and Fife, D. (2021). Risk of Aortic Aneurysm and Dissection Following Exposure to Fluoroquinolones, Common Antibiotics, and Febrile Illness Using a Self-Controlled Case Series Study Design: Retrospective Analyses of Three Large Healthcare Databases in the US. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0255887"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Jun, C., and Fang, B. (2021). Current Progress of Fluoroquinolones-Increased Risk of Aortic Aneurysm and Dissection. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-021-02258-1"},{"key":"ref_176","unstructured":"(2021, August 12). George Sakoulas Adverse Effects of Fluoroquinolones: Where Do We Stand?. Available online: https:\/\/www.jwatch.org\/na48248\/2019\/02\/13\/adverse-effects-fluoroquinolones-where-do-we-stand."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/cvr\/cvt089","article-title":"Biomechanical Factors as Triggers of Vascular Growth","volume":"99","author":"Hoefer","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/0194599816633671","article-title":"Ciprofloxacin Decreases Collagen in Mouse Tympanic Membrane Fibroblasts","volume":"155","author":"Orobello","year":"2016","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ijantimicag.2009.10.009","article-title":"Synergistic Effects of Dexamethasone and Quinolones on Human-Derived Tendon Cells","volume":"35","author":"Sendzik","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.cjca.2017.07.092","article-title":"Fluoroquinolone induces human aortic fibroblast-mediated extracellular matrix dysregulation","volume":"33","author":"Guzzardi","year":"2017","journal-title":"Can. J. Cardiol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"11153","DOI":"10.3390\/molecules180911153","article-title":"Metal Complexes of Quinolone Antibiotics and Their Applications: An Update","volume":"18","author":"Uivarosi","year":"2013","journal-title":"Molecules"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Walden, D.M., Khotimchenko, M., Hou, H., Chakravarty, K., and Varshney, J. (2021). Effects of Magnesium, Calcium, and Aluminum Chelation on Fluoroquinolone Absorption Rate and Bioavailability: A Computational Study. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13050594"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1128\/AAC.38.12.2810","article-title":"Effect of Magnesium Complexation by Fluoroquinolones on Their Antibacterial Properties","volume":"38","author":"Lecomte","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"24","DOI":"10.14194\/ijmbr.115","article-title":"Biological Activities of Some Fluoroquinolones-Metal Complexes","volume":"1","author":"Akinremi","year":"2012","journal-title":"Int. J. Med. Biomed. Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"22287","DOI":"10.1074\/jbc.M115.671222","article-title":"Nonantibiotic Effects of Fluoroquinolones in Mammalian Cells","volume":"290","author":"Badal","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.44.2.261-266.2000","article-title":"Ultrastructure of Achilles Tendons of Rats Treated with Ofloxacin and Fed a Normal or Magnesium-Deficient Diet","volume":"44","author":"Shakibaei","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s002040050010","article-title":"Effects of Magnesium Deficiency on Joint Cartilage in Immature Beagle Dogs: Immunohistochemistry, Electron Microscopy, and Mineral Concentrations","volume":"73","author":"Stahlmann","year":"2000","journal-title":"Arch. Toxicol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e010077","DOI":"10.1136\/bmjopen-2015-010077","article-title":"Fluoroquinolones and Collagen Associated Severe Adverse Events: A Longitudinal Cohort Study","volume":"5","author":"Daneman","year":"2015","journal-title":"BMJ Open"},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Yu, P.-H., Hu, C.-F., Liu, J.-W., Chung, C.-H., Chen, Y.-C., Sun, C.-A., and Chien, W.-C. (2020). The Incidence of Collagen-Associated Adverse Events in Pediatric Population with the Use of Fluoroquinolones: A Nationwide Cohort Study in Taiwan. BMC Pediatr., 20.","DOI":"10.1186\/s12887-020-1962-0"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s40265-017-0790-5","article-title":"Delafloxacin: First Global Approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"ofy220","DOI":"10.1093\/ofid\/ofy220","article-title":"Safety of Delafloxacin: Focus on Adverse Events of Special Interest","volume":"5","author":"Lodise","year":"2018","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_192","unstructured":"(2022, September 19). Office of the Commissioner FDA Updates Warnings for Fluoroquinolone Antibiotics on Risks of Mental Health and Low Blood Sugar Adverse Reactions, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-updates-warnings-fluoroquinolone-antibiotics-risks-mental-health-and-low-blood-sugar-adverse."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.amjms.2022.01.016","article-title":"Early Clinical Experience with Delafloxacin: A Case Series","volume":"363","author":"Hornak","year":"2022","journal-title":"Am. J. Med. Sci."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40265-022-01725-z","article-title":"Delafloxacin: A Review in Community-Acquired Pneumonia","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00003495-199958002-00007","article-title":"Toxicity of Quinolones","volume":"58","author":"Stahlmann","year":"1999","journal-title":"Drugs"},{"key":"ref_196","first-page":"49","article-title":"The Risk of Fluoroquinolone-Induced Tendinopathy and Tendon Rupture","volume":"3","author":"Kim","year":"2010","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1179544119835222","DOI":"10.1177\/1179544119835222","article-title":"Bilateral Levofloxacin-Induced Achilles Tendon Rupture: An Uncommon Case Report and Review of the Literature","volume":"12","year":"2019","journal-title":"Clin. Med. Insights Arthritis Musculoskelet. Disord."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1080\/00365540310015863","article-title":"Levofloxacin-Associated Achilles Tendon Rupture and Tendinopathy","volume":"35","author":"Melhus","year":"2003","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3122\/jabfm.16.5.458","article-title":"Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature","volume":"16","author":"Gold","year":"2003","journal-title":"J. Am. Board Fam. Pract."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00776-003-0761-4","article-title":"Levofloxacin-Induced Bilateral Achilles Tendon Rupture: A Case Report and Review of the Literature","volume":"9","author":"Kowatari","year":"2004","journal-title":"J. Orthop. Sci."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"e034844","DOI":"10.1136\/bmjopen-2019-034844","article-title":"Association between Tendon Ruptures and Use of Fluoroquinolone, and Other Oral Antibiotics: A 10-Year Retrospective Study of 1 Million US Senior Medicare Beneficiaries","volume":"10","author":"Baik","year":"2020","journal-title":"BMJ Open"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/01.NOR.0000276969.09808.2c","article-title":"Pathogenesis of Tendon Rupture Secondary to Fluoroquinolone Therapy","volume":"26","author":"Childs","year":"2007","journal-title":"Orthop. Nurs."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/03635465000280031401","article-title":"The Effect of Ciprofloxacin on Tendon, Paratenon, and Capsular Fibroblast Metabolism","volume":"28","author":"Williams","year":"2000","journal-title":"Am. J. Sports Med."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13318-018-0520-8","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin","volume":"44","author":"Shiu","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/13543784.2020.1750595","article-title":"Innovative Therapies for Acute Bacterial Skin and Skin-Structure Infections (ABSSSI) Caused by Methicillin-Resistant Staphylococcus Aureus: Advances in Phase I and II Trials","volume":"29","author":"Bassetti","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy165","article-title":"PROCEED Study Group A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin with Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study","volume":"67","author":"McManus","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"PROCEED Study Group Efficacy and Safety of Delafloxacin Compared with Vancomycin plus Aztreonam for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Double-Blind, Randomized Study","volume":"72","author":"Pullman","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_208","first-page":"ofz514","article-title":"DEFINE-CABP Study Group A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada","year":"2020","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_209","unstructured":"Blair, K., and Czyz, C.N. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/d41586-018-03267-5","article-title":"When Antibiotics Turn Toxic","volume":"555","author":"Marchant","year":"2018","journal-title":"Nature"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2012.383","article-title":"Oral Fluoroquinolones and the Risk of Retinal Detachment","volume":"307","author":"Etminan","year":"2012","journal-title":"JAMA"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1001\/jama.2013.280500","article-title":"Association Between Oral Fluoroquinolone Use and Retinal Detachment","volume":"310","author":"Pasternak","year":"2013","journal-title":"JAMA"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1001\/jama.2013.280501","article-title":"Oral Fluoroquinolone Use and Retinal Detachment: Reconciling Conflicting Findings in Observational Research","volume":"310","author":"Brett","year":"2013","journal-title":"JAMA"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/pds.3623","article-title":"Risk of Retinal Tear or Detachment with Oral Fluoroquinolone Use: A Cohort Study","volume":"23","author":"Eftekhari","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jac\/dku507","article-title":"Association between Oral Fluoroquinolone Use and the Development of Retinal Detachment: A Systematic Review and Meta-Analysis of Observational Studies","volume":"70","author":"Chui","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jamaophthalmol.2016.3479","article-title":"Oral Fluoroquinolone Use and Retinal Detachment-Reply","volume":"134","author":"Raguideau","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jamaophthalmol.2016.3477","article-title":"Oral Fluoroquinolone Use and Retinal Detachment","volume":"134","author":"Douglas","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s40261-018-0708-3","article-title":"Signal Detection Between Fluoroquinolone Use and the Risk of Rhegmatogenous Retinal Detachment: Sequence Symmetry Analysis Using Nationwide South Korean Healthcare Database Between 2004 and 2015","volume":"38","author":"Baek","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1093\/jac\/dky336","article-title":"The Risk Profile of Rhegmatogenous Retinal Detachment before and after Using a Fluoroquinolone: A 12 Year Nationwide Self-Controlled Case Series Study","volume":"73","author":"Shin","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_220","first-page":"369","article-title":"Systemic Quinolones and Risk of Retinal Detachment II: Systematic Review of Clinical Trials","volume":"8","author":"Taher","year":"2021","journal-title":"Clin. Med. Rev. Case Rep."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/14740338.2022.1993187","article-title":"Systemic Quinolones and Risk of Retinal Detachment I: Analysis of Data from the US FDA Adverse Event Reporting System","volume":"21","author":"Taher","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00228-021-03260-4","article-title":"Systemic Quinolones and Risk of Retinal Detachment III: A Nested Case-Control Study Using a US Electronic Health Records Database","volume":"78","author":"Taher","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1167\/iovs.07-1456","article-title":"Collagen Distribution in the Human Vitreoretinal Interface","volume":"49","author":"Ponsioen","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Reviglio, V.E., Hakim, M.A., Song, J.K., and O\u2019Brien, T.P. (2003). Effect of Topical Fluoroquinolones on the Expression of Matrix Metalloproteinases in the Cornea. BMC Ophthalmol., 3.","DOI":"10.1186\/1471-2415-3-10"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/15376516.2010.529183","article-title":"Effect of Fluoroquinolones on the Expression of Matrix Metalloproteinase in Debrided Cornea of Rats","volume":"21","author":"Sharma","year":"2011","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1086\/375078","article-title":"Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature","volume":"36","author":"Khaliq","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccc.2007.12.011","article-title":"Antibiotic Adverse Reactions and Drug Interactions","volume":"24","author":"Granowitz","year":"2008","journal-title":"Crit. Care Clin."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/jac\/37.4.831","article-title":"Peripheral Sensory Disturbances Related to Treatment with Fluoroquinolones","volume":"37","author":"Hedenmalm","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1345\/aph.1Z429","article-title":"Peripheral Neuropathy Associated with Fluoroquinolones","volume":"35","author":"Cohen","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaneurol.2019.0887","article-title":"Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy","volume":"76","author":"Morales","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_231","first-page":"124","article-title":"Severe Acute Axonal Neuropathy Induced by Ciprofloxacin: A Case Report","volume":"10","author":"Popescu","year":"2018","journal-title":"CRN"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"2324709614545225","DOI":"10.1177\/2324709614545225","article-title":"Permanent Peripheral Neuropathy: A Case Report on a Rare but Serious Debilitating Side-Effect of Fluoroquinolone Administration","volume":"2","author":"Francis","year":"2014","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"2324709617752736","DOI":"10.1177\/2324709617752736","article-title":"Quinolone-Induced Painful Peripheral Neuropathy: A Case Report and Literature Review","volume":"6","author":"Estofan","year":"2018","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3389\/fphar.2020.00428","article-title":"Quinolones-Induced Musculoskeletal, Neurological, and Psychiatric ADRs: A Pharmacovigilance Study Based on Data from the Italian Spontaneous Reporting System","volume":"11","author":"Scavone","year":"2020","journal-title":"Front. Pharm."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/TCRM.S284171","article-title":"How Safe Are Fluoroquinolones for Diabetic Patients? A Systematic Review of Dysglycemic and Neuropathic Effects of Fluoroquinolones","volume":"17","author":"Althaqafi","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_236","unstructured":"(2022, November 09). Menarini Group A Randomized, Observer-Blinded, Active-Controlled, Phase Illb Study to Compare IV\/Oral Delafloxacin Fixed-Dose Monotherapy With Best Available Treatments in a Microbiologically Enriched Population With Surgical Site Infections; clinicaltrials.gov, 2022, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04042077."},{"key":"ref_237","first-page":"255","article-title":"Phase III Double-Blind Comparative Study of Lascufloxacin versus Levofloxacin in Patients with Community-Acquired Pneumonia|Cochrane Library","volume":"69","author":"Miki","year":"2021","journal-title":"Jpn. J. Chemother."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1128\/AAC.00683-09","article-title":"Multiple-Dose Safety, Tolerability, and Pharmacokinetics of Oral Nemonoxacin (TG-873870) in Healthy Volunteers","volume":"54","author":"Chung","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1128\/AAC.00295-10","article-title":"Efficacy and Safety of Nemonoxacin versus Levofloxacin for Community-Acquired Pneumonia","volume":"54","author":"Perng","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jmii.2015.09.005","article-title":"A Randomized, Double-Blind, Multicenter Phase II Study Comparing the Efficacy and Safety of Oral Nemonoxacin with Oral Levofloxacin in the Treatment of Community-Acquired Pneumonia","volume":"50","author":"Liu","year":"2017","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s10156-012-0514-4","article-title":"Clinical and Bacteriological Efficacies of Sitafloxacin against Community-Acquired Pneumonia Caused by Streptococcus Pneumoniae: Nested Cohort within a Multicenter Clinical Trial","volume":"19","author":"Fujita","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1185\/03007995.2013.825591","article-title":"Comparison of Pharmacokinetics between New Quinolone Antibiotics: The Zabofloxacin Hydrochloride Capsule and the Zabofloxacin Aspartate Tablet","volume":"29","author":"Han","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/COPD.S90948","article-title":"Zabofloxacin versus Moxifloxacin in Patients with COPD Exacerbation: A Multicenter, Double-Blind, Double-Dummy, Randomized, Controlled, Phase III, Non-Inferiority Trial","volume":"10","author":"Rhee","year":"2015","journal-title":"Int. J. Chron. Obs. Pulmon. Dis."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/11587280-000000000-00000","article-title":"Quinolones: Review of Psychiatric and Neurological Adverse Reactions","volume":"34","author":"Filipe","year":"2011","journal-title":"Drug Saf."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"54","DOI":"10.12788\/jcso.0167","article-title":"Fluoroquinolone-Related Neuropsychiatric and Mitochondrial Toxicity: A Collaborative Investigation by Scientists and Members of a Social Network","volume":"14","author":"Kaur","year":"2016","journal-title":"J. Community Support Oncol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s00213-016-4300-3","article-title":"Quinolone Antibiotics and Suicidal Behavior: Analysis of the World Health Organization\u2019s Adverse Drug Reactions Database and Discussion of Potential Mechanisms","volume":"233","author":"Samyde","year":"2016","journal-title":"Psychopharmacology"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.psym.2017.11.001","article-title":"Fluoroquinolone-Related Neuropsychiatric Events in Hospitalized Veterans","volume":"59","author":"Sellick","year":"2018","journal-title":"Psychosomatics"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1345\/aph.10359","article-title":"Seizures Associated with Fluoroquinolones","volume":"35","author":"Kushner","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3390\/neurosci2030017","article-title":"Fluoroquinolones-Associated Disability: It Is Not All in Your Head","volume":"2","author":"Freeman","year":"2021","journal-title":"NeuroSci"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0025-7125(05)70297-2","article-title":"Clinical Use of the Fluoroquinolones","volume":"84","author":"Owens","year":"2000","journal-title":"Med. Clin. N. Am."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1128\/AAC.33.10.1704","article-title":"Structure-Epileptogenicity Relationship of Quinolones with Special Reference to Their Interaction with Gamma-Aminobutyric Acid Receptor Sites","volume":"33","author":"Akahane","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijid.2014.10.009","article-title":"A Randomized Phase 2 Study Comparing Two Doses of Delafloxacin with Tigecycline in Adults with Complicated Skin and Skin-Structure Infections","volume":"30","author":"Mehra","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","article-title":"Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties","volume":"7","author":"Jorgensen","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"ref_254","unstructured":"Jjingo, C.J. (2022, November 10). Clinical Review (Baxdela) 2016, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208610Orig1s000,208611Orig1s000MedR.pdf."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/106002809202600229","article-title":"Comment: Myasthenia Gravis and Ciprofloxacin","volume":"26","author":"Maddix","year":"1992","journal-title":"Ann. Pharmacother."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0006-8993(95)01349-0","article-title":"Effects of the Quinoline Derivatives Quinine, Quinidine, and Chloroquine on Neuromuscular Transmission","volume":"712","author":"Sieb","year":"1996","journal-title":"Brain Res."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.annemergmed.2004.01.027","article-title":"Fluoroquinolones Should Be Avoided in Myasthenia Gravis","volume":"44","author":"Tintinalli","year":"2004","journal-title":"Ann. Emerg. Med."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1136\/emj.2006.038091","article-title":"Levofloxacin Induced Myasthenia Crisis","volume":"23","author":"Gunduz","year":"2006","journal-title":"Emerg Med. J."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/mus.27230","article-title":"Pharmacosafety of Fluoroquinolone and Macrolide Antibiotics in the Clinical Care of Patients with Myasthenia Gravis","volume":"64","author":"Leonard","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0041-0101(96)00147-X","article-title":"Efficacy of Certain Quinolines as Pharmacological Antagonists in Botulinum Neurotoxin Poisoning","volume":"35","author":"Deshpande","year":"1997","journal-title":"Toxicon"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1212\/WNL.50.3.804","article-title":"Fluoroquinolone Antibiotics Block Neuromuscular Transmission","volume":"50","author":"Sieb","year":"1998","journal-title":"Neurology"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0895-4356(98)00041-9","article-title":"Skin Reactions to Antibacterial Agents in General Practice","volume":"51","author":"Vlug","year":"1998","journal-title":"J. Clin. Epidemiol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/15569527.2017.1319379","article-title":"Cutaneous Allergic Drug Reactions: Update on Pathophysiology, Diagnostic Procedures and Differential Diagnosic","volume":"36","author":"Balakirski","year":"2017","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0738-081X(02)00322-X","article-title":"Quinolones in Dermatology","volume":"21","author":"Sable","year":"2003","journal-title":"Clin. Dermatol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11882-005-0049-1","article-title":"Hypersensitivity Reactions to Fluoroquinolones","volume":"5","author":"Scherer","year":"2005","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_266","first-page":"003180","article-title":"Anaphylaxis to Ciprofloxacin Requiring Emergent Surgical Cricothyrotomy","volume":"9","author":"Tang","year":"2022","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_267","unstructured":"EMA (2022, September 22). Factive: Withdrawn Application. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/withdrawn-applications\/factive."},{"key":"ref_268","unstructured":"(2022, September 22). Menarini International Operations Luxembourg S.A. Withdrawal Letter Factive. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/withdrawal-letter-factive_en.pdf."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"280","DOI":"10.5415\/apallergy.2012.2.4.280","article-title":"Biphasic Anaphylaxis to Gemifloxacin","volume":"2","author":"Yilmaz","year":"2012","journal-title":"Asia Pac. Allergy"},{"key":"ref_270","doi-asserted-by":"crossref","unstructured":"McGee, E.U., Samuel, E., Boronea, B., Dillard, N., Milby, M.N., and Lewis, S.J. (2019). Quinolone Allergy. Pharmacy, 7.","DOI":"10.3390\/pharmacy7030097"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/all.12168","article-title":"Severe Drug-Induced Anaphylaxis: Analysis of 333 Cases Recorded by the Allergy Vigilance Network from 2002 to 2010","volume":"68","author":"Renaudin","year":"2013","journal-title":"Allergy"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2003.09.035","article-title":"Detection of Specific IgE to Quinolones","volume":"113","author":"Manfredi","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2310\/6620.2011.10115","article-title":"Cutaneous Adverse Reactions to Fluoroquinolones","volume":"22","author":"Kulthanan","year":"2011","journal-title":"Dermatitis"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.18203\/2319-2003.ijbcp20172017","article-title":"Comparative Analysis of Cutaneous Drug Reactions among Different Fluoroquinolones: An Experimental Study","volume":"6","author":"Devadarshini","year":"2017","journal-title":"Int. J. Basic Clin. Pharmacol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.clinbiochem.2015.04.006","article-title":"Quinolones-Induced Hypersensitivity Reactions","volume":"48","author":"Neuman","year":"2015","journal-title":"Clin. Biochem."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"AB40","DOI":"10.1016\/j.jaci.2015.12.133","article-title":"Anaphylactic Shock Caused By Moxifloxacin without Cross-Reactivity to Other Fluoroquinolones","volume":"137","author":"Li","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11882-017-0725-y","article-title":"Update on Quinolone Allergy","volume":"17","author":"Moreno","year":"2017","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s40521-020-00260-0","article-title":"Quinolone-Induced Anaphylaxis","volume":"7","author":"Portilho","year":"2020","journal-title":"Curr. Treat. Options Allergy"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"e3679","DOI":"10.1097\/MD.0000000000003679","article-title":"Hypersensitivity to Fluoroquinolones","volume":"95","author":"Ariza","year":"2016","journal-title":"Medicine"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.jaip.2020.04.051","article-title":"Clinical Characterization and Diagnostic Approaches for Patients Reporting Hypersensitivity Reactions to Quinolones","volume":"8","author":"Salas","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"292","DOI":"10.18176\/jiaci.0669","article-title":"Clinical Practice Guidelines for Diagnosis and Management of Hypersensitivity Reactions to Quinolones","volume":"31","author":"Boteanu","year":"2021","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.intimp.2019.02.001","article-title":"Mast Cell-Mediated Hypersensitivity to Fluoroquinolone Is MRGPRX2 Dependent","volume":"70","author":"Liu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"e02297-17","DOI":"10.1128\/AAC.02297-17","article-title":"Intrapulmonary Pharmacokinetics of Levonadifloxacin Following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects","volume":"62","author":"Rodvold","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1128\/AAC.00682-09","article-title":"Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Nemonoxacin (TG-873870), a Novel Potent Broad-Spectrum Nonfluorinated Quinolone, in Healthy Volunteers","volume":"54","author":"Lin","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/11632780-000000000-00000","article-title":"Safety and Clinical Pharmacokinetics of Nemonoxacin, a Novel Non-Fluorinated Quinolone, in Healthy Chinese Volunteers following Single and Multiple Oral Doses","volume":"32","author":"Guo","year":"2012","journal-title":"Clin. Drug Investig."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1128\/AAC.04039-14","article-title":"Pharmacokinetics and Pharmacodynamics of Multiple-Dose Intravenous Nemonoxacin in Healthy Chinese Volunteers","volume":"59","author":"Wu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/1574886308666140106154754","article-title":"Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles","volume":"9","author":"Sousa","year":"2014","journal-title":"Curr. Drug Saf."},{"key":"ref_288","unstructured":"Singh, A.P., Kumar, V., and Singh, N. (2012). Phototoxic Potential Assessment of Enoxacin In Vitro: Phototoxicity, LAP LAMBERT Academic Publishing."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-0781.1999.tb00094.x","article-title":"In Vitro Phototoxicity of New Quinolones: Production of Active Oxygen Species and Photosensitized Lipid Peroxidation","volume":"15","author":"Kawada","year":"1999","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_290","doi-asserted-by":"crossref","unstructured":"Ja\u0142brzykowska, K., Chrzanowska, A., Roszkowski, P., and Struga, M. (2022). The New Face of a Well-Known Antibiotic: A Review of the Anticancer Activity of Enoxacin and Its Derivatives. Cancers, 14.","DOI":"10.3390\/cancers14133056"},{"key":"ref_291","doi-asserted-by":"crossref","unstructured":"Johansen, J.D., Frosch, P.J., and Lepoittevin, J.-P. (2011). Contact Dermatitis, Springer.","DOI":"10.1007\/978-3-642-03827-3"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1751-1097.2011.00978.x","article-title":"Photosensitization Reactions of Fluoroquinolones and Their Biological Consequences","volume":"87","author":"Bracchitta","year":"2011","journal-title":"Photochem. Photobiol."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0041-008X(91)90026-B","article-title":"Mechanistic Studies of the Phototoxic Potential of PD 117596, a Quinolone Antibacterial Compound","volume":"111","author":"Robertson","year":"1991","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0027-5107(98)00189-4","article-title":"Mechanisms of Photosensitization by Phototoxic Drugs","volume":"422","author":"Moore","year":"1998","journal-title":"Mutat. Res. Fundam. Mol. Mech. Mutagen."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1011-1344(98)00160-2","article-title":"Photocleavage of DNA by the Fluoroquinolone Antibacterials","volume":"45","author":"Chignell","year":"1998","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.36.8.1715","article-title":"Photostability and Biological Activity of Fluoroquinolones Substituted at the 8 Position after UV Irradiation","volume":"36","author":"Matsumoto","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1442-9071.2007.01552.x","article-title":"Ocular Toxicity of Fluoroquinolones","volume":"35","author":"Thompson","year":"2007","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1383-5718(00)00034-6","article-title":"Differences in the Photogenotoxic Potential of Two Fluoroquinolones as Shown in Diploid Yeast Strain (Saccharomyces Cerevisae) and Supercoiled Plasmid DNA","volume":"468","author":"Marrot","year":"2000","journal-title":"Mutat. Res."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1039\/a703226i","article-title":"The Photochemistry of Lomefloxacin. An Aromatic Carbene as the Keyintermediate in Photodecomposition","volume":"14","author":"Fasani","year":"1997","journal-title":"Chem. Commun."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1021\/jp060634d","article-title":"Generation of Detectable Singlet Aryl Cations by Photodehalogenation of Fluoroquinolones","volume":"110","author":"Cuquerella","year":"2006","journal-title":"J. Phys. Chem. B"},{"key":"ref_301","doi-asserted-by":"crossref","unstructured":"Kowalska, J., Banach, K., Rok, J., Beberok, A., Rzepka, Z., and Wrze\u015bniok, D. (2020). Molecular and Biochemical Basis of Fluoroquinolones-Induced Phototoxicity\u2014The Study of Antioxidant System in Human Melanocytes Exposed to UV-A Radiation. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249714"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cbdv.200490061","article-title":"Photophysical and Phototoxic Properties of the Antibacterial Fluoroquinolones Levofloxacin and Moxifloxacin","volume":"1","author":"Viola","year":"2004","journal-title":"Chem. Biodivers."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1039\/c8pp00019k","article-title":"Lack of Phototoxicity Potential with Delafloxacin in Healthy Male and Female Subjects: Comparison to Lomefloxacin","volume":"17","author":"Dawe","year":"2018","journal-title":"Photochem. Photobiol. Sci."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jat.4300","article-title":"Preclinical Safety Evaluation of Levonadifloxacin, a Novel Anti-Methicillin-Resistant Staphyloccocus Aureus Benzoquinolizine Fluoroquinolone by Intravenous and Oral Administration","volume":"42","author":"Nandanwar","year":"2022","journal-title":"J. Appl. Toxicol."},{"key":"ref_305","unstructured":"Chugh, R., Lakdavala, F., and Bhatia, A. (2016). Proceedings of the Abstract P1268, European Society of Clinical Microbiology and Infectious Diseases."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"128432","DOI":"10.1016\/j.bmcl.2021.128432","article-title":"Design and Synthesis of an Oral Prodrug Alalevonadifloxacin for the Treatment of MRSA Infection","volume":"54","author":"Bhawsar","year":"2021","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1365-2133.2003.05582.x","article-title":"A Randomized Controlled Trial (Volunteer Study) of Sitafloxacin, Enoxacin, Levofloxacin and Sparfloxacin Phototoxicity","volume":"149","author":"Dawe","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/archderm.1994.01690040068009","article-title":"Skin Pigmentation as a Predictor of Minimal Phototoxic Dose after Oral Methoxsalen","volume":"130","author":"Angelo","year":"1994","journal-title":"Arch. Dermatol."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/IDR.S178183","article-title":"Oral Sitafloxacin vs Intravenous Ceftriaxone Followed by Oral Cefdinir for Acute Pyelonephritis and Complicated Urinary Tract Infection: A Randomized Controlled Trial","volume":"12","author":"Lojanapiwat","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_310","first-page":"CD004610","article-title":"Antibiotic Treatment for Clostridium Difficile-associated Diarrhoea in Adults","volume":"2017","author":"Nelson","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1128\/AAC.00592-06","article-title":"Are Broad-Spectrum Fluoroquinolones More Likely To Cause Clostridium Difficile-Associated Disease?","volume":"50","author":"Dhalla","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0924-8579(09)70013-5","article-title":"Clostridium Difficile and Fluoroquinolones: Is There a Link?","volume":"33","author":"Weiss","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3201\/eid0906.020385","article-title":"Fluoroquinolone Use and Clostridium Difficile\u2013Associated Diarrhea","volume":"9","author":"McCusker","year":"2003","journal-title":"Emerg. Infect. Dis."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1185\/030079908X253735","article-title":"Do Fluoroquinolones Predispose Patients to Clostridium Difficile Associated Disease? A Review of the Evidence","volume":"24","author":"Deshpande","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jinf.2009.03.010","article-title":"Recurrent Clostridium Difficile Infection: A Review of Risk Factors, Treatments, and Outcomes","volume":"58","author":"Johnson","year":"2009","journal-title":"J. Infect."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"010417","DOI":"10.7189\/jogh.07.010417","article-title":"Risk Factors for Clostridium Difficile Infections\u2014An Overview of the Evidence Base and Challenges in Data Synthesis","volume":"7","author":"Eze","year":"2017","journal-title":"J. Glob. Health"},{"key":"ref_317","doi-asserted-by":"crossref","unstructured":"Davies, K., Lawrence, J., Berry, C., Davis, G., Yu, H., Cai, B., Gonzalez, E., Prantner, I., Kurcz, A., and Macovei, I. (2020). Risk Factors for Primary Clostridium Difficile Infection; Results from the Observational Study of Risk Factors for Clostridium Difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID). Front. Public Health, 8.","DOI":"10.3389\/fpubh.2020.00293"},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3201\/eid1604.090859","article-title":"Fluoroquinolone Resistance and Clostridium Difficile, Germany","volume":"16","author":"Zaiss","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1473-3099(17)30052-X","article-title":"Fluoroquinolone Restriction to Control Fluoroquinolone-Resistant Clostridium Difficile","volume":"17","author":"Donskey","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_320","unstructured":"(2022, November 14). Kyorin Pharmacetical Lasvic Tablets 75mg. Available online: https:\/\/www.rad-ar.or.jp\/siori\/english\/search\/result?n=42565."},{"key":"ref_321","first-page":"e24299","article-title":"Real-World Evidence of Efficacy and Safety of Levonadifloxacin (Oral and IV) in the Management of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Findings of a Retrospective, Multi-Center Study","volume":"14","author":"Mehta","year":"2022","journal-title":"Cureus"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/med.20019","article-title":"QT Prolongation through HERG K+ Channel Blockade: Current Knowledge and Strategies for the Early Prediction during Drug Development","volume":"25","author":"Recanatini","year":"2005","journal-title":"Med. Res. Rev."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.7150\/ijms.34141","article-title":"Torsades de Pointes and QT Prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System","volume":"16","author":"Teng","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1124\/mol.59.1.122","article-title":"Interactions of a Series of Fluoroquinolone Antibacterial Drugs with the Human Cardiac K+ Channel HERG","volume":"59","author":"Kang","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2165\/00003495-200464100-00005","article-title":"QT Prolongation with Antimicrobial Agents","volume":"64","author":"Owens","year":"2004","journal-title":"Drugs"},{"key":"ref_326","first-page":"103","article-title":"QT Prolongation and Torsade de Pointes Induced by Fluoroquinolones: Infrequent Side Effects from Commonly Used Medications","volume":"120","author":"Briasoulis","year":"2011","journal-title":"CRD"},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/jac\/49.4.593","article-title":"Cardiotoxicity of Fluoroquinolones","volume":"49","author":"Rubinstein","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMcp0706513","article-title":"Long-QT Syndrome","volume":"358","author":"Roden","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14740338.2018.1520837","article-title":"Moxifloxacin-Induced QT Interval Prolongation and Torsades de Pointes: A Narrative Review","volume":"17","author":"Khan","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1592\/phco.21.3.301.34206","article-title":"Risk Assessment for Antimicrobial Agent-Induced QTc Interval Prolongation and Torsades de Pointes","volume":"21","author":"Owens","year":"2001","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.hrthm.2004.06.020","article-title":"Ciprofloxacin-Induced Acquired Long QT Syndrome","volume":"1","author":"Prabhakar","year":"2004","journal-title":"Heart Rhythm."},{"key":"ref_332","first-page":"172","article-title":"Ciprofloxacin Induced Acquired Long QT Syndrome in a Patient under Class III Antiarrhythmic Therapy","volume":"16","author":"Keivanidou","year":"2009","journal-title":"Cardiol. J."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0009-9236(03)00009-2","article-title":"Effects of Three Fluoroquinolones on QT Interval in Healthy Adults after Single Doses","volume":"73","author":"Noel","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1542-474X.2006.00082.x","article-title":"Effects of Three Fluoroquinolones on QT Analysis after Standard Treatment Courses","volume":"11","author":"Tsikouris","year":"2006","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.mayocp.2015.02.011","article-title":"Rare Incidence of Ventricular Tachycardia and Torsades de Pointes in Hospitalized Patients with Prolonged QT Who Later Received Levofloxacin: A Retrospective Study","volume":"90","author":"Stancampiano","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MAJ.0b013e3181a3c2c9","article-title":"Moxifloxacin-Induced QT Prolongation and Torsades: An Uncommon Effect of a Common Drug","volume":"338","author":"Badshah","year":"2009","journal-title":"Am. J. Med. Sci."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jphs.2018.01.009","article-title":"Effects of Moxifloxacin on the Proarrhythmic Surrogate Markers in Healthy Filipino Subjects: Exposure-Response Modeling Using ECG Data of Thorough QT\/QTc Study","volume":"136","author":"Matsukura","year":"2018","journal-title":"J. Pharmacol. Sci."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jcph.1534","article-title":"Effects of the Fluoroquinolones Moxifloxacin and Levofloxacin on the QT Subintervals: Sex Differences in Ventricular Repolarization","volume":"60","author":"Prasad","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bcp.12168","article-title":"Thorough QT Study of the Effect of Oral Moxifloxacin on QTc Interval in the Fed and Fasted State in Healthy Japanese and Caucasian Subjects","volume":"77","author":"Taubel","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1128\/AAC.04813-14","article-title":"A Thorough QT Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of Delafloxacin on Cardiac Repolarization","volume":"59","author":"Litwin","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/cts.12594","article-title":"Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone","volume":"12","author":"Mason","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/aps.2014.95","article-title":"Effects of an Al3+- and Mg2+-Containing Antacid, Ferrous Sulfate, and Calcium Carbonate on the Absorption of Nemonoxacin (TG-873870) in Healthy Chinese Volunteers","volume":"35","author":"Zhang","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2147\/DDDT.S95934","article-title":"Effects of Probenecid and Cimetidine on the Pharmacokinetics of Nemonoxacin in Healthy Chinese Volunteers","volume":"10","author":"Zhang","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.clinthera.2018.04.014","article-title":"Effects of Nemonoxacin on thorough ECG QT\/QTc Interval: A Randomized, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Adults","volume":"40","author":"Zhao","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.clinthera.2019.01.015","article-title":"Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients with Moderate Hepatic Impairment","volume":"41","author":"Kang","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.amjmed.2009.07.022","article-title":"Quinolone-Induced Hypoglycemia: A Life-Threatening but Potentially Reversible Side Effect","volume":"123","author":"Kelesidis","year":"2010","journal-title":"Am. J. Med."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"109225","DOI":"10.1016\/j.diabres.2022.109225","article-title":"Comparative Risk of Serious Hypoglycemia among Persons Dispensed a Fluoroquinolone versus a Non-Fluoroquinolone Antibiotic","volume":"185","author":"Ellis","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pcd.2014.10.006","article-title":"Dysglycemia Associated with Quinolones","volume":"9","author":"Azar","year":"2015","journal-title":"Prim. Care Diabetes"},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.amjmed.2008.10.003","article-title":"Levofloxacin-Induced Hypoglycemia: A Rare but Life-Threatening Side Effect of a Widely Used Antibiotic","volume":"122","author":"Kelesidis","year":"2009","journal-title":"Am. J. Med."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1056\/NEJMoa055191","article-title":"Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults","volume":"354","author":"Juurlink","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.clinthera.2006.11.014","article-title":"Gatifloxacin-Induced Hyperglycemia: A Case Report and Summary of the Current Literature","volume":"28","author":"Yip","year":"2006","journal-title":"Clin. Ther."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/01.smj.0000197047.39522.07","article-title":"Hyperglycemia in an Elderly Diabetic Patient: Drug-Drug or Drug-Disease Interaction?","volume":"99","author":"Bobba","year":"2006","journal-title":"South. Med. J."},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1210\/jc.2008-1416","article-title":"Drug-Induced Hypoglycemia: A Systematic Review","volume":"94","author":"Murad","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1248\/bpb.29.527","article-title":"Effects of Gatifloxacin on Serum Glucose Concentration in Normal and Diabetic Rats","volume":"29","author":"Ishiwata","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jac\/dkv411","article-title":"A Randomized, Double-Blind, Phase 2 Study to Evaluate Subjective and Objective Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infections Treated with Delafloxacin, Linezolid or Vancomycin","volume":"71","author":"Kingsley","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jiac.2019.09.010","article-title":"Pharmacokinetic Study of Lascufloxacin in Non-Elderly Healthy Men and Elderly Men","volume":"26","author":"Totsuka","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"e02169-17","DOI":"10.1128\/AAC.02169-17","article-title":"Intrapulmonary Pharmacokinetics of Lascufloxacin in Healthy Adult Volunteers","volume":"62","author":"Furuie","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_358","unstructured":"(2020). LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases."},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"114915","DOI":"10.1016\/j.taap.2020.114915","article-title":"The Hepatotoxic Fluoroquinolone Trovafloxacin Disturbs TNF- and LPS-Induced P65 Nuclear Translocation in Vivo and in Vitro","volume":"391","author":"Giustarini","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s15010-009-9179-z","article-title":"Hepatotoxicity of Antibacterials: Pathomechanisms and Clinical Data","volume":"38","author":"Leitner","year":"2010","journal-title":"Infection"},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkr159","article-title":"Hepatic Safety of Antibiotics Used in Primary Care","volume":"66","author":"Andrade","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1310\/hpj4411-978","article-title":"Ciprofloxacin-Induced Hepatotoxicity Resolved with Levofloxacin: A Case Report and a Review of the Literature","volume":"44","author":"Hirsch","year":"2009","journal-title":"Hosp. Pharm."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cgh.2011.02.019","article-title":"Clinical and Histopathologic Features of Fluoroquinolone-Induced Liver Injury","volume":"9","author":"Orman","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2146\/ajhp130165","article-title":"Risk of Hepatotoxicity Associated with Fluoroquinolones: A National Case\u2013Control Safety Study","volume":"71","author":"Alshammari","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jgh3.12585","article-title":"Systemic Quinolones and Risk of Acute Liver Failure I: Analysis of Data from the US FDA Adverse Event Reporting System","volume":"5","author":"Taher","year":"2021","journal-title":"JGH Open"},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1016\/j.bmcl.2007.10.070","article-title":"Mechanisms of Trovafloxacin Hepatotoxicity: Studies of a Model Cyclopropylamine-Containing System","volume":"17","author":"Sun","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clinthera.2015.10.016","article-title":"Single and Multiple Ascending-Dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age","volume":"38","author":"Hoover","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy\u2019s Law: Predicting Serious Hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jmii.2017.07.011","article-title":"Safety and Efficacy of Oral Nemonoxacin versus Levofloxacin in Treatment of Community-Acquired Pneumonia: A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Non-Inferiority Trial","volume":"52","author":"Yuan","year":"2019","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s10156-012-0543-z","article-title":"Clinical Dose Findings of Sitafloxacin Treatment: Pharmacokinetic-Pharmacodynamic Analysis of Two Clinical Trial Results for Community-Acquired Respiratory Tract Infections","volume":"19","author":"Kohno","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/etc.5620170305","article-title":"Identification of Fluoroquinolone Antibiotics as the Main Source of UmuC Genotoxicity in Native Hospital Wastewater","volume":"17","author":"Hartmann","year":"1998","journal-title":"Environ. Toxicol. Chem."},{"key":"ref_372","first-page":"309","article-title":"Genotoxic Evaluation of the Antibacterial Drug, Ciprofloxacin, in Cultured Lymphocytes of Patients with Urinary Tract Infection","volume":"34","author":"Ikbal","year":"2004","journal-title":"Turk. J. Med. Sci."},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1021\/es070031v","article-title":"Quantitative Structure\u2212Activity Relationship Model for Prediction of Genotoxic Potential for Quinolone Antibacterials","volume":"41","author":"Hu","year":"2007","journal-title":"Environ. Sci. Technol."},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ecoenv.2011.10.012","article-title":"Assessment of the Genotoxicity of Quinolone and Fluoroquinolones Contaminated Soil with the Vicia Faba Micronucleus Test","volume":"76","author":"Khadra","year":"2012","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/01480545.2013.851691","article-title":"In Silico and in Vitro Genotoxicity Evaluation of Descarboxyl Levofloxacin, an Impurity in Levofloxacin","volume":"37","author":"Zhu","year":"2014","journal-title":"Drug Chem. Toxicol."},{"key":"ref_376","doi-asserted-by":"crossref","unstructured":"Du, M., Zhang, D., Hou, Y., Zhao, X., and Li, Y. (2019). Combined 2D-QSAR, Principal Component Analysis and Sensitivity Analysis Studies on Fluoroquinolones\u2019 Genotoxicity. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16214156"},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"34830","DOI":"10.1007\/s11356-019-06482-3","article-title":"Combined HQSAR Method and Molecular Docking Study on Genotoxicity Mechanism of Quinolones with Higher Genotoxicity","volume":"26","author":"Zhao","year":"2019","journal-title":"Environ. Sci. Pollut. Res."},{"key":"ref_378","unstructured":"(2022, November 17). PubChem Amifloxacin, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/55492."},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1358\/dof.2009.034.03.1350294","article-title":"Nemonoxacin Quinolone Antibiotic","volume":"34","author":"Arjona","year":"2009","journal-title":"Drug Future"},{"key":"ref_380","first-page":"765","article-title":"Review of Nemonoxacin with Special Focus on Clinical Development","volume":"8","author":"Qin","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.chemosphere.2013.09.002","article-title":"Genotoxicity of Quinolones: Substituents Contribution and Transformation Products QSAR Evaluation Using 2D and 3D Models","volume":"95","author":"Li","year":"2014","journal-title":"Chemosphere"},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"117634","DOI":"10.1016\/j.saa.2019.117634","article-title":"Fluoroquinolone Antibiotics Show Genotoxic Effect through DNA-Binding and Oxidative Damage","volume":"227","author":"Bhattacharya","year":"2020","journal-title":"Spectrochim. Acta Part A Mol. Biomol. Spectrosc."},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ecoenv.2016.10.036","article-title":"Analysis of Positions and Substituents on Genotoxicity of Fluoroquinolones with Quantitative Structure-Activity Relationship and 3D Pharmacophore Model","volume":"136","author":"Fengxian","year":"2017","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"e00120-17","DOI":"10.1128\/AAC.00120-17","article-title":"In Vitro Activities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977)","volume":"61","author":"Kishii","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref_385","unstructured":"(2020). Taigexyn\u00ae Nemonoxacin Capsule 250 Mg, TaiGen Biotechnology Co., Ltd."},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.1442-200X.1999.4121038.x","article-title":"Effect of Early Oral Fluoroquinolones in Hemorrhagic Colitis Due to Escherichia Coli O157:H7","volume":"41","author":"Shiomi","year":"1999","journal-title":"Pediatr. Int."},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jama.288.8.996","article-title":"Risk of Hemolytic Uremic Syndrome after Antibiotic Treatment of Escherichia Coli O157:H7 Enteritis: A Meta-Analysis","volume":"288","author":"Safdar","year":"2002","journal-title":"JAMA"},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-2036.2006.03036.x","article-title":"Systematic Review: Are Antibiotics Detrimental or Beneficial for the Treatment of Patients with Escherichia Coli O157:H7 Infection?","volume":"24","author":"Panos","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"442","DOI":"10.7883\/yoken.65.442","article-title":"Does Levofloxacin Induce Hemolytic Uremic Syndrome in Patients Infected with Verotoxin-Producing Escherichia Coli O157 Infections?","volume":"65","author":"Ohnishi","year":"2012","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s15010-012-0387-6","article-title":"Ciprofloxacin Reduces the Risk of Hemolytic Uremic Syndrome in Patients with Escherichia Coli O104:H4-Associated Diarrhea","volume":"41","author":"Fritzsche","year":"2013","journal-title":"Infection"},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jinf.2019.05.018","article-title":"Shiga Toxin-Induced Haemolytic Uraemic Syndrome and the Role of Antibiotics: A Global Overview","volume":"79","author":"Kakoullis","year":"2019","journal-title":"J. Infect."},{"key":"ref_392","doi-asserted-by":"crossref","unstructured":"Mody, R.K., Hoekstra, R.M., Scott, M.K., Dunn, J., Smith, K., Tobin-D\u2019Angelo, M., Shiferaw, B., Wymore, K., Clogher, P., and Palmer, A. (2021). Risk of Hemolytic Uremic Syndrome Related to Treatment of Escherichia Coli O157 Infection with Different Antimicrobial Classes. Microorganisms, 9.","DOI":"10.3390\/microorganisms9091997"},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.2830460420","article-title":"Hemolytic Anemia and Acute Renal Failure Associated with Temafloxacin-Dependent Antibodies","volume":"46","author":"Maguire","year":"1994","journal-title":"Am. J. Hematol."},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1358\/dot.2000.36.4.570201","article-title":"Pharmacokinetics and Metabolism of Moxifloxacin","volume":"36","author":"Moise","year":"2000","journal-title":"Drugs Today"},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/17425255.2012.674512","article-title":"Fluoroquinolone Disposition: Identification of the Contribution of Renal Secretory and Reabsorptive Drug Transporters","volume":"8","author":"Mulgaonkar","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_396","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00002018-200022060-00006","article-title":"Fluoroquinolone-Induced Renal Failure","volume":"22","author":"Lomaestro","year":"2000","journal-title":"Drug Saf."},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/11531490-000000000-00000","article-title":"Safety Considerations of Fluoroquinolones in the Elderly","volume":"27","author":"Stahlmann","year":"2010","journal-title":"Drugs Aging"},{"key":"ref_398","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1503\/cmaj.121730","article-title":"Risk of Acute Kidney Injury Associated with the Use of Fluoroquinolones","volume":"185","author":"Bird","year":"2013","journal-title":"CMAJ"},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2017.08.024","article-title":"Clinical Manifestations and Outcomes of Fluoroquinolone-Related Acute Interstitial Nephritis","volume":"93","author":"Farid","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.ajkd.2007.05.014","article-title":"Ciprofloxacin Crystal Nephropathy","volume":"50","author":"Stratta","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"ref_401","first-page":"29","article-title":"Crystal-Induced Acute Kidney Injury Due to Ciprofloxacin","volume":"4","author":"Khan","year":"2015","journal-title":"J. Nephropathol."},{"key":"ref_402","unstructured":"Gilbert, S.J., and Weiner, D.E. (2014). National Kidney Foundation Primer on Kidney Diseases, W.B. Saunders. [6th ed.]."},{"key":"ref_403","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3329\/bjsir.v50i4.25833","article-title":"In Vitro Evaluation of Ciprofloxacin Hydrochloride","volume":"50","author":"Jaman","year":"2015","journal-title":"Bangladesh J. Sci. Ind. Res."},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0378-5173(95)04332-2","article-title":"The Effect of PH, Buffer Type and Drug Concentration on the Photodegradation of Ciprofloxacin","volume":"132","author":"Torniainen","year":"1996","journal-title":"Int. J. Pharm."},{"key":"ref_405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clay.2015.05.010","article-title":"Influence of PH and Antibiotic Solubility on the Removal of Ciprofloxacin from Aqueous Media Using Montmorillonite","volume":"114","author":"Baschini","year":"2015","journal-title":"Appl. Clay Sci."},{"key":"ref_406","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/jcph.1041","article-title":"Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function","volume":"58","author":"Hoover","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_407","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinthera.2015.11.019","article-title":"Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers","volume":"38","author":"Hoover","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jcph.1099","article-title":"Pharmacokinetics of Intravenous Delafloxacin in Patients With End-Stage Renal Disease","volume":"58","author":"Hoover","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_409","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1365-2125.2000.00212.x","article-title":"The Link between Sunshine and Phototoxicity of Sparfloxacin","volume":"49","author":"Pierfitte","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_410","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0887-2333(02)00029-2","article-title":"Phototoxic Effect of Fluoroquinolones on Two Human Cell Lines","volume":"16","author":"Trisciuoglio","year":"2002","journal-title":"Toxicol Vitr."},{"key":"ref_411","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.annemergmed.2007.06.493","article-title":"Comparison of Octreotide and Standard Therapy versus Standard Therapy Alone for the Treatment of Sulfonylurea-Induced Hypoglycemia","volume":"51","author":"Fasano","year":"2008","journal-title":"Ann. Emerg. Med."},{"key":"ref_412","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1067\/mem.2000.108183","article-title":"Octreotide: An Antidote for Sulfonylurea-Induced Hypoglycemia","volume":"36","author":"McLaughlin","year":"2000","journal-title":"Ann. Emerg. Med."},{"key":"ref_413","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/emj.2007.051326","article-title":"Use of Octreotide Acetate to Prevent Rebound Hypoglycaemia in Sulfonylurea Overdose","volume":"24","author":"Hassan","year":"2007","journal-title":"Emerg. Med. J."},{"key":"ref_414","doi-asserted-by":"crossref","first-page":"e2224892","DOI":"10.1001\/jamanetworkopen.2022.24892","article-title":"Association of Higher-Dose Fluoroquinolone Therapy with Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease","volume":"5","author":"Muanda","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_415","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s15010-016-0885-z","article-title":"Strategies to Enhance Rational Use of Antibiotics in Hospital: A Guideline by the German Society for Infectious Diseases","volume":"44","author":"Allerberger","year":"2016","journal-title":"Infection"},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13017-016-0089-y","article-title":"Antimicrobials: A Global Alliance for Optimizing Their Rational Use in Intra-Abdominal Infections (AGORA)","volume":"11","author":"Sartelli","year":"2016","journal-title":"World J. Emerg. Surg."},{"key":"ref_417","doi-asserted-by":"crossref","first-page":"20646","DOI":"10.4236\/pp.2012.33044","article-title":"Fluoroquinolones Reported Hepatotoxicity","volume":"3","author":"Adikwu","year":"2012","journal-title":"Pharmacol. Pharm."},{"key":"ref_418","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00192-021-05013-4","article-title":"Efficacy and Safety of Quinolones vs. Other Antimicrobials for the Treatment of Uncomplicated Urinary Tract Infections in Adults: A Systematic Review and Meta-Analysis","volume":"33","author":"Yan","year":"2022","journal-title":"Int. Urogynecol. J."},{"key":"ref_419","first-page":"427","article-title":"Adverse Reactions of Fluoroquinolones to Central Nervous System and Rational Drug Use in Nursing Care","volume":"32","author":"Haiping","year":"2019","journal-title":"Pak. J. Pharm. Sci."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/3\/804\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:45:05Z","timestamp":1760121905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/3\/804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":419,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["pharmaceutics15030804"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15030804","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}